Jiangsu Simcere Pharmaceutical Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin-protein ligase binding moiety coupled to an interleukin-1 receptor-associated kinase 4 (IRAK-4)-targeting moiety through a linker reported to be useful for the treatment of cancer, neurodegeneration, infections, autoimmune and inflammatory disorders.

Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.

Yuhan Corp. has disclosed mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.

Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer.

Shanghai Yiweikang Pharmaceutical Co. Ltd. has divulged camptothecin derivatives acting as DNA topoisomerase I inhibitors reported to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has identified peptide-drug conjugates comprising a peptide targeting integrin αvβ3 (vitronectin) covalently bound to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.

Quantx Biosciences US Inc. has synthesized interleukin-17A/A homodimer and/or IL-17A/F heterodimer inhibitors reported to be useful for the treatment of autoimmune and inflammatory diseases.

Revolution Medicines Inc. has disclosed macrocyclic compounds acting as GTPase KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer.

Raythera Inc. has described C-C chemokine receptor type 4 (CCR4) antagonists reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, systemic lupus erythematosus, atherosclerosis, asthma, chronic obstructive pulmonary disease and multiple sclerosis, among others.